AMSTERDAM, Nov 9 (Reuters) - Dutch biotech firm Crucell (CRCL.AS), the subject of a cash offer by Johnson & Johnson, reported a third-quarter loss as it took a charge related to production problems of vaccines at a South Korean plant.
AMSTERDAM, Nov 9 (Reuters) - Dutch biotech firm Crucell (CRCL.AS), the subject of a cash offer by Johnson & Johnson, reported a third-quarter loss as it took a charge related to production problems of vaccines at a South Korean plant.
